Trials / No Longer Available
No Longer AvailableNCT00302016
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMN107 |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-11-01
- First posted
- 2006-03-13
- Last updated
- 2011-08-26
Locations
270 sites across 34 countries: United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Lebanon, Malaysia, Mexico, Netherlands, Norway, Poland, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00302016. Inclusion in this directory is not an endorsement.